| 1 |
34337566 |
10.1016/j.xcrm.2021.100350 |
2022 |
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. |
HRAS |
| 2 |
34341476 |
10.1038/s10038-021-00965-3 |
2022 |
PAX3/7-FOXO1 fusion-negative alveolar rhabdomyosarcoma in Schuurs-Hoeijmakers syndrome. |
HRAS |
| 3 |
35092381 |
10.31557/APJCP.2022.23.1.131 |
2022 |
Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. |
HRAS |
| 4 |
35192832 |
10.1016/j.scitotenv.2022.153990 |
2022 |
Effects of gestational exposure to bisphenol A on the hepatic transcriptome and lipidome of rat dams: Intergenerational comparison of effects in the offspring. |
HRAS |
| 5 |
35363510 |
10.1200/JCO.21.02840 |
2022 |
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. |
HRAS |
| 6 |
35674396 |
10.1093/bioinformatics/btac380 |
2022 |
Prediction of Allosteric Communication Pathways in Proteins. |
HRAS |
| 7 |
35981360 |
10.19746/j.cnki.issn.1009-2137.2022.04.011 |
2022 |
[The Effect of KRAS on Proliferation and Apoptosis of T-ALL Cell Lines]. |
HRAS |
| 8 |
32147503 |
10.1016/j.jid.2020.02.019 |
2021 |
Recurrent Oncogenic JAK and STAT Alterations in Cutaneous CD30-Positive Lymphoproliferative Disorders. |
HRAS |
| 9 |
33016928 |
10.1172/JCI139080 |
2021 |
Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. |
HRAS |
| 10 |
33297669 |
10.3324/haematol.2020.267294 |
2021 |
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. |
HRAS |
| 11 |
33397922 |
10.1038/s41467-020-20255-4 |
2021 |
A RAC-GEF network critical for early intestinal tumourigenesis. |
HRAS |
| 12 |
33512434 |
10.1182/blood.2020009082 |
2021 |
Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors. |
HRAS |
| 13 |
33750196 |
10.1200/JCO.20.02903 |
2021 |
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. |
HRAS |
| 14 |
34302028 |
10.1038/s41598-021-94566-x |
2021 |
Development of thymic tumor in [LSL:Kras<sup>G12D</sup>; Pdx1-CRE] mice, an adverse effect associated with accelerated pancreatic carcinogenesis. |
HRAS |
| 15 |
30087949 |
10.1210/js.2018-00132 |
2020 |
Synchronous Independent Papillary Thyroid Carcinomas in Struma Ovarii and the Thyroid Gland With Different <i>RAS</i> Mutations. |
HRAS |
| 16 |
30946933 |
10.1016/j.humpath.2019.03.004 |
2020 |
The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. |
HRAS |
| 17 |
32188628 |
10.1136/jclinpath-2020-206461 |
2020 |
Transcriptome complexity in intravascular NK/T-cell lymphoma. |
HRAS |
| 18 |
32620621 |
10.21873/anticanres.14371 |
2020 |
Anti-tumor Properties of <i>Picrasma quassioides</i> Extracts in H-Ras<sup>G12V</sup> Liver Cancer Are Mediated Through ROS-dependent Mitochondrial Dysfunction. |
HRAS |
| 19 |
29636358 |
10.1158/1078-0432.CCR-17-2452 |
2019 |
Resistance Mechanisms to Targeted Therapies in <i>ROS1</i><sup>+</sup> and <i>ALK</i><sup>+</sup> Non-small Cell Lung Cancer. |
HRAS |
| 20 |
29661787 |
10.1182/blood-2018-01-827949 |
2019 |
Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. |
HRAS |
| 21 |
29950132 |
10.1080/15548627.2018.1466013 |
2019 |
Role of the MAPK/cJun NH<sub>2</sub>-terminal kinase signaling pathway in starvation-induced autophagy. |
HRAS |
| 22 |
30875092 |
10.1002/bem.22177 |
2019 |
Carcinogenicity of intermediate frequency magnetic field in Tg.rasH2 mice. |
HRAS |
| 23 |
31199785 |
10.1371/journal.pgen.1008168 |
2019 |
Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias. |
HRAS |
| 24 |
27034005 |
10.18632/oncotarget.8427 |
2018 |
Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. |
HRAS |
| 25 |
27102345 |
10.1038/modpathol.2016.79 |
2018 |
Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies. |
HRAS |
| 26 |
27484103 |
10.1080/07391102.2016.1188417 |
2018 |
An integrated approach of network-based systems biology, molecular docking, and molecular dynamics approach to unravel the role of existing antiviral molecules against AIDS-associated cancer. |
HRAS |
| 27 |
28262675 |
10.1038/ncomms14581 |
2018 |
Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene. |
HRAS |
| 28 |
29923908 |
10.1097/DAD.0000000000001014 |
2018 |
ALK Rearrangements Are Infrequent in Cellular Blue Nevus and Deep Penetrating Nevus. |
HRAS |
| 29 |
30257940 |
10.1073/pnas.1721678115 |
2018 |
PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. |
HRAS |
| 30 |
26675036 |
10.1177/1066896915622261 |
2017 |
Epithelial-Myoepithelial Carcinoma of the Salivary Gland Harboring HRAS Codon 61 Mutations With Lung Metastasis. |
HRAS |
| 31 |
26873340 |
10.1177/1066896916630375 |
2017 |
Spitz Tumors: Comparison of Histological Features in Relationship to Immunohistochemical Staining for ALK and NTRK1. |
HRAS |
| 32 |
27017489 |
10.1007/s00204-016-1696-9 |
2017 |
Twenty-six-week oral carcinogenicity study of 3-monochloropropane-1,2-diol in CB6F1-rasH2 transgenic mice. |
HRAS |
| 33 |
27055865 |
10.1038/leu.2016.40 |
2017 |
Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis. |
HRAS |
| 34 |
27488117 |
10.1007/s13277-016-5283-8 |
2017 |
IQGAP1 gene silencing induces apoptosis and decreases the invasive capacity of human hepatocellular carcinoma cells. |
HRAS |
| 35 |
27696251 |
10.1007/s12020-016-1080-9 |
2017 |
Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. |
HRAS |
| 36 |
28235199 |
10.1016/j.cell.2017.02.006 |
2017 |
Multivalent Small-Molecule Pan-RAS Inhibitors. |
HRAS |
| 37 |
28425994 |
10.1038/nature22056 |
2017 |
Modulating the therapeutic response of tumours to dietary serine and glycine starvation. |
HRAS |
| 38 |
26399548 |
10.1038/ncomms9477 |
2016 |
Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma. |
HRAS |
| 39 |
26507119 |
10.1080/15592294.2015.1110672 |
2016 |
Epigenetic instability at imprinting control regions in a Kras(G12D)-induced T-cell neoplasm. |
HRAS |
| 40 |
26855057 |
10.1016/j.ejmg.2016.01.003 |
2016 |
Acute lymphoblastic leukemia in the context of RASopathies. |
HRAS |
| 41 |
27013922 |
10.2174/1389202916666151014221954 |
2016 |
Genetics of Bladder Malignant Tumors in Childhood. |
HRAS |
| 42 |
25371176 |
10.1038/leu.2014.315 |
2015 |
Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice. |
HRAS |
| 43 |
25387078 |
10.3390/ijms151120500 |
2015 |
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer. |
HRAS |
| 44 |
25602801 |
10.1097/PAS.0000000000000387 |
2015 |
Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. |
HRAS |
| 45 |
23751074 |
10.1111/pcmr.12129 |
2014 |
Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. |
HRAS |
| 46 |
24505083 |
10.1182/blood-2013-01-477620 |
2014 |
Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy. |
HRAS |
| 47 |
22575864 |
10.1038/modpathol.2012.73 |
2013 |
Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. |
HRAS |
| 48 |
22684892 |
10.1002/ijc.27668 |
2013 |
Ikaros is a critical target during simultaneous exposure to X-rays and N-ethyl-N-nitrosourea in mouse T-cell lymphomagenesis. |
HRAS |
| 49 |
22792269 |
10.1371/journal.pone.0040302 |
2013 |
The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer. |
HRAS |
| 50 |
22976127 |
10.1038/leu.2012.251 |
2013 |
Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals. |
HRAS |
| 51 |
23183424 |
10.1038/leu.2012.316 |
2013 |
Differential roles of Kras and Pten in murine leukemogenesis. |
HRAS |
| 52 |
23392229 |
10.1097/JTO.0b013e318283558e |
2013 |
Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. |
HRAS |
| 53 |
23673656 |
10.1074/jbc.M113.475376 |
2013 |
Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation. |
HRAS |
| 54 |
21045156 |
10.1158/0008-5472.CAN-10-1568 |
2011 |
Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling. |
HRAS |
| 55 |
20194733 |
10.1073/pnas.1001064107 |
2010 |
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. |
HRAS |
| 56 |
18827450 |
10.2131/jts.33.493 |
2009 |
Carcinogenic comparative study on rasH2 mice produced by two breeding facilities. |
HRAS |
| 57 |
19066392 |
10.1182/blood-2008-01-134262 |
2009 |
Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. |
HRAS |
| 58 |
19296721 |
10.1371/journal.pbio.1000059 |
2009 |
Oncogenic Kras initiates leukemia in hematopoietic stem cells. |
HRAS |
| 59 |
19543317 |
10.1038/onc.2009.165 |
2009 |
BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. |
HRAS |
| 60 |
19765110 |
10.1111/j.1365-2613.2009.00667.x |
2009 |
Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. |
HRAS |
| 61 |
16923573 |
10.1080/10428190600565925 |
2007 |
Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations. |
HRAS |
| 62 |
16969076 |
10.4161/cbt.5.8.3251 |
2007 |
Recurrent KRAS codon 146 mutations in human colorectal cancer. |
HRAS |
| 63 |
17251932 |
10.1038/nature05541 |
2007 |
Restoration of p53 function leads to tumour regression in vivo. |
HRAS |
| 64 |
17483702 |
10.1097/MPH.0b013e3180547136 |
2007 |
Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. |
HRAS |
| 65 |
12393503 |
10.1182/blood-2002-08-2434 |
2003 |
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. |
HRAS |
| 66 |
12650030 |
|
2003 |
[Clinical importance of semi-quantitative monitoring of lymphomas using the comparative polymerase chain reaction]. |
HRAS |
| 67 |
12970747 |
10.1038/sj.onc.1206766 |
2003 |
Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. |
HRAS |
| 68 |
11748353 |
10.3346/jkms.2001.16.6.731 |
2002 |
Expressions of p53 and p21 in primary gastric lymphomas. |
HRAS |
| 69 |
12134164 |
10.1038/ncb833 |
2002 |
Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. |
HRAS |
| 70 |
11351252 |
10.3892/ijo.18.6.1207 |
2001 |
Helicobacter pylori eradication therapy for high-grade mucosa-associated lymphoid tissue lymphomas of the stomach with analysis of p53 and K-ras alteration and microsatellite instability. |
HRAS |
| 71 |
10634643 |
10.1016/s0145-2126(99)00157-5 |
2000 |
Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice. |
HRAS |
| 72 |
10730886 |
|
2000 |
Monitoring of residual disease in non-Hodgkin's lymphomas by quantitative PCR (preliminary report). |
HRAS |
| 73 |
10769750 |
10.2144/00284st08 |
2000 |
Optimized multiplex IgH/ras PCR: a tool for quantitative monitoring of B-lymphoproliferative disorders. |
HRAS |
| 74 |
9563642 |
10.1016/s0304-3835(97)00530-2 |
1998 |
MNNG-transformed Bloom syndrome B-lymphoblastoids for the detection of Hodgkin's lymphoma-associated antigen in 2D Westerns. |
HRAS |
| 75 |
8940017 |
10.1074/jbc.271.48.30499 |
1997 |
Human type II Fcgamma receptors inhibit B cell activation by interacting with the p21(ras)-dependent pathway. |
HRAS |
| 76 |
8970991 |
10.1128/JVI.70.12.8653-8659.1996 |
1997 |
Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. |
HRAS |
| 77 |
9052860 |
10.1016/s0165-2478(96)02655-7 |
1997 |
Integration of activatory and inhibitory signals in human B-cells. |
HRAS |
| 78 |
9111865 |
10.1016/s0065-230x(08)60098-6 |
1997 |
Functional aspects of apoptosis in hematopoiesis and consequences of failure. |
HRAS |
| 79 |
8816388 |
|
1996 |
Activation of the Ras signaling pathway by the CD40 receptor. |
HRAS |
| 80 |
7547984 |
10.1021/bi00038a037 |
1995 |
Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirements. |
HRAS |
| 81 |
7761357 |
10.1007/s002920050084 |
1995 |
[Apoptosis and cell proliferation in HHV-6 infections. Regulatory mechanisms of p53/bcl-2/ras interactions]. |
HRAS |
| 82 |
7784061 |
|
1995 |
TTF, a gene encoding a novel small G protein, fuses to the lymphoma-associated LAZ3 gene by t(3;4) chromosomal translocation. |
HRAS |
| 83 |
8112727 |
10.1002/hon.2900110303 |
1994 |
Association between ATL and non-hematopoietic neoplasms. |
HRAS |
| 84 |
1295465 |
|
1993 |
The expression of the ras p21 oncoprotein in the bone marrow smears of children with acute leukemia. |
HRAS |
| 85 |
8505202 |
|
1993 |
Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. |
HRAS |
| 86 |
1313398 |
10.1002/ijc.2910500610 |
1992 |
Serum oncoproteins and growth factors in asbestosis and silicosis patients. |
HRAS |
| 87 |
1373069 |
10.3109/08880019209006397 |
1992 |
Oncogene RNA expression in three human lymphoblastic leukemia cell lines lymphocytes. |
HRAS |
| 88 |
1628649 |
10.1111/j.1432-1033.1992.tb17039.x |
1992 |
Generation of specific antibodies against the rap1A, rap1B and rap2 small GTP-binding proteins. Analysis of rap and ras proteins in membranes from mammalian cells. |
HRAS |
| 89 |
1737360 |
|
1992 |
Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. |
HRAS |
| 90 |
1746900 |
|
1992 |
Implication of the ras and myc oncoproteins in the pathogenesis of mycosis fungoides. |
HRAS |
| 91 |
1773791 |
10.1289/ehp.919319 |
1992 |
ras activation in human tumors and in animal model systems. |
HRAS |
| 92 |
2040694 |
10.1172/JCI115234 |
1991 |
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. |
HRAS |
| 93 |
1699752 |
10.1507/endocrj1954.37.247 |
1990 |
Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies. |
HRAS |
| 94 |
1976194 |
10.1016/0140-6736(90)93302-6 |
1990 |
Co-expression of N-ras p21 and C-erbB-2 (neu) oncogene products by common ALL antigen-positive aggressive diffuse lymphoma. |
HRAS |
| 95 |
2183888 |
|
1990 |
The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. |
HRAS |
| 96 |
2687507 |
|
1990 |
[Studies on association between the ATL and the development of multiple malignant neoplasms--analysis of 1171 cases of hematological malignancies during the past 24 years]. |
HRAS |
| 97 |
2511175 |
10.1111/j.1349-7006.1989.tb01701.x |
1989 |
Increased expression of ras genes in non-Hodgkin's lymphomas is not associated with oncogenic activation of those genes by point mutation. |
HRAS |
| 98 |
2563124 |
10.1016/s0140-6736(89)91233-6 |
1989 |
Multiple primary malignant neoplasms in patients with adult T-cell leukaemia. |
HRAS |
| 99 |
2681441 |
10.1002/stem.5530070603 |
1989 |
ras mutations in human leukemia and related disorders. |
HRAS |
| 100 |
3065747 |
10.1016/S0344-0338(88)80050-5 |
1989 |
Interaction between transforming growth factor-alpha and c-Ha-ras p21 in progression of human gastric carcinoma. |
HRAS |
Datasets
Models
